BR112019018649A2 - inibidores jak derivados da fusão de imidazopiperidina - Google Patents

inibidores jak derivados da fusão de imidazopiperidina Download PDF

Info

Publication number
BR112019018649A2
BR112019018649A2 BR112019018649A BR112019018649A BR112019018649A2 BR 112019018649 A2 BR112019018649 A2 BR 112019018649A2 BR 112019018649 A BR112019018649 A BR 112019018649A BR 112019018649 A BR112019018649 A BR 112019018649A BR 112019018649 A2 BR112019018649 A2 BR 112019018649A2
Authority
BR
Brazil
Prior art keywords
compound
alkyl
petition
pct
disease
Prior art date
Application number
BR112019018649A
Other languages
English (en)
Portuguese (pt)
Inventor
Smith Cameron
E L Brandt Gary
D Crater Glenn
Jean Van Orden Lori
A Kleinschek Melanie
R Fatheree Paul
d e sullivan Steven
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of BR112019018649A2 publication Critical patent/BR112019018649A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
BR112019018649A 2017-03-09 2018-03-08 inibidores jak derivados da fusão de imidazopiperidina BR112019018649A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
PCT/US2018/021492 WO2018165395A1 (en) 2017-03-09 2018-03-08 Fused imidazo-piperidine jak inhibitors

Publications (1)

Publication Number Publication Date
BR112019018649A2 true BR112019018649A2 (pt) 2020-04-07

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112019018649A BR112019018649A2 (pt) 2017-03-09 2018-03-08 inibidores jak derivados da fusão de imidazopiperidina
BR112019018648-4A BR112019018648A2 (pt) 2017-03-09 2018-03-08 Inibidores de jak contendo uma amida heterocíclica com 4 membros

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112019018648-4A BR112019018648A2 (pt) 2017-03-09 2018-03-08 Inibidores de jak contendo uma amida heterocíclica com 4 membros

Country Status (20)

Country Link
US (10) US10208040B2 (enExample)
EP (2) EP3592742B1 (enExample)
JP (2) JP7134990B2 (enExample)
KR (2) KR102526764B1 (enExample)
CN (2) CN110382498B (enExample)
AR (2) AR111242A1 (enExample)
AU (2) AU2018231032B2 (enExample)
BR (2) BR112019018649A2 (enExample)
CA (1) CA2997772A1 (enExample)
DK (1) DK3592742T3 (enExample)
EA (2) EA037748B1 (enExample)
ES (1) ES2882186T3 (enExample)
IL (2) IL268689B2 (enExample)
MX (2) MX388750B (enExample)
PH (2) PH12019501941A1 (enExample)
PT (1) PT3592742T (enExample)
SG (2) SG11201907840RA (enExample)
TW (2) TWI754019B (enExample)
WO (2) WO2018165395A1 (enExample)
ZA (2) ZA201905585B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3371185T3 (pl) * 2015-11-03 2021-04-06 Topivert Pharma Limited Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
MX374605B (es) 2015-11-03 2025-03-06 Theravance Biopharma R&D Ip Llc Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
EP3837258B1 (en) 2018-09-04 2024-04-24 Theravance Biopharma R&D IP, LLC Dimethyl amino azetidine amides as jak inhibitors
EA202190686A1 (ru) * 2018-09-04 2021-07-23 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи 5-7-членные гетероциклические амиды в качестве ингибиторов jak
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
JP2022506111A (ja) * 2018-10-29 2022-01-17 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤としての2-アザビシクロヘキサン化合物
HUE067145T2 (hu) 2019-02-25 2024-10-28 Henan Medinno Pharmaceutical Tech Co Ltd JAK inhibitor vegyület és alkalmazása
IL285999B1 (en) 2019-03-05 2025-09-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
CN114901659A (zh) * 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
JP7580136B2 (ja) * 2019-12-30 2024-11-11 路良 Jak阻害剤化合物及びその使用
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
TW202317550A (zh) * 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形
CN117658852A (zh) * 2023-11-15 2024-03-08 西北工业大学 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用
WO2025157904A1 (en) * 2024-01-24 2025-07-31 Kiox Pharmaceuticals Aps Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof
CN118903009B (zh) * 2024-10-11 2025-01-21 江苏长泰药业股份有限公司 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
JP5651681B2 (ja) 2009-04-03 2015-01-14 大日本住友製薬株式会社 代謝型グルタミン酸受容体5介在障害の治療のための化合物、およびその使用方法
US8450340B2 (en) 2009-12-21 2013-05-28 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
NZ720092A (en) 2013-12-05 2019-05-31 Pfizer Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3865481A1 (en) 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
MX374605B (es) 2015-11-03 2025-03-06 Theravance Biopharma R&D Ip Llc Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
PL3371185T3 (pl) 2015-11-03 2021-04-06 Topivert Pharma Limited Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
TWI808083B (zh) 2017-05-01 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶型式
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
EA202190686A1 (ru) 2018-09-04 2021-07-23 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EP3837258B1 (en) 2018-09-04 2024-04-24 Theravance Biopharma R&D IP, LLC Dimethyl amino azetidine amides as jak inhibitors

Also Published As

Publication number Publication date
AU2018231035B2 (en) 2021-09-09
KR102526764B1 (ko) 2023-04-27
CA2997772A1 (en) 2018-09-09
EP3592743A1 (en) 2020-01-15
US20200181141A1 (en) 2020-06-11
KR102533646B1 (ko) 2023-05-17
TW201837037A (zh) 2018-10-16
US20220289737A1 (en) 2022-09-15
US10519153B2 (en) 2019-12-31
US10392386B2 (en) 2019-08-27
TW201840560A (zh) 2018-11-16
US20210269436A1 (en) 2021-09-02
US20190127371A1 (en) 2019-05-02
EA037261B1 (ru) 2021-03-01
AU2018231032B2 (en) 2021-08-19
ES2882186T3 (es) 2021-12-01
US20230063643A1 (en) 2023-03-02
AU2018231032A1 (en) 2019-09-05
US10550118B2 (en) 2020-02-04
MX388749B (es) 2025-03-11
IL268679A (en) 2019-10-31
MX2019010541A (es) 2019-10-21
JP7134990B2 (ja) 2022-09-12
CN110382498B (zh) 2022-07-12
ZA201905618B (en) 2021-05-26
IL268679B (en) 2021-10-31
US11254669B2 (en) 2022-02-22
IL268689A (en) 2019-10-31
CN110461839B (zh) 2022-08-23
CN110382498A (zh) 2019-10-25
IL268689B (en) 2022-10-01
AU2018231032A8 (en) 2019-10-17
MX388750B (es) 2025-03-20
ZA201905585B (en) 2020-05-27
NZ756823A (en) 2021-04-30
PH12019501985A1 (en) 2020-10-05
JP2020510015A (ja) 2020-04-02
CN110461839A (zh) 2019-11-15
EA037748B1 (ru) 2021-05-18
PH12019501941A1 (en) 2020-07-06
US20190337945A1 (en) 2019-11-07
TWI779016B (zh) 2022-10-01
PT3592742T (pt) 2021-07-30
AR111242A1 (es) 2019-06-19
US10196393B2 (en) 2019-02-05
US10208040B2 (en) 2019-02-19
BR112019018648A2 (pt) 2020-06-16
US20180258088A1 (en) 2018-09-13
MX2019010539A (es) 2019-10-21
EA201992126A1 (ru) 2020-02-05
IL268689B2 (en) 2023-02-01
KR20190127798A (ko) 2019-11-13
US11667637B2 (en) 2023-06-06
EA201992128A1 (ru) 2020-01-29
US10954237B2 (en) 2021-03-23
WO2018165392A1 (en) 2018-09-13
SG11201907544VA (en) 2019-09-27
US11453668B2 (en) 2022-09-27
EP3592742A1 (en) 2020-01-15
SG11201907840RA (en) 2019-09-27
WO2018165395A1 (en) 2018-09-13
TWI754019B (zh) 2022-02-01
AR111241A1 (es) 2019-06-19
US20190119275A1 (en) 2019-04-25
JP6974487B2 (ja) 2021-12-01
US20180258087A1 (en) 2018-09-13
EP3592742B1 (en) 2021-05-19
US11878977B2 (en) 2024-01-23
JP2020510010A (ja) 2020-04-02
US20200216447A1 (en) 2020-07-09
AU2018231035A1 (en) 2019-09-05
KR20190127796A (ko) 2019-11-13
DK3592742T3 (da) 2021-08-09

Similar Documents

Publication Publication Date Title
BR112019018649A2 (pt) inibidores jak derivados da fusão de imidazopiperidina
KR102826491B1 (ko) Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
ES2955717T3 (es) Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
EA040464B1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2822 DE 04/02/2025.